Cited by 312Genetic Neurodegenerative DiseasesCoenzyme Q10 studies and effectsNeurological diseases and metabolism

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

The Huntington Study Group·2001·Neurology

Open this paper in CoChat — free account

Abstract

OBJECTIVES: To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD). METHODS: The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events. RESULTS: Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10. CONCLUSIONS: Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.

Integrity signals

Registry

Crossref · 10.1212/wnl.57.3.397

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unified Huntington's disease rating scale: Reliability and consistency
Kremer, H. P. H. (1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,155
The hopkins verbal learning test: Development of a new memory test with six equivalent forms
Brandt, J. (1991) · Clinical Neuropsychologist · doi:10.1080/13854049108403297 · Cited by 1,317
Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Self-citation
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals
Penney, J. B., Young, A. B., Shoulson, I., Starosta‐Rubinstein, S., Snodgrass, S. R., Sanchez‐Ramos, J., Ramos‐Arroyo, M. A., Gomez, F., Penchaszadeh, G. K., Alvir, J., et al. (1990) · Movement Disorders · doi:10.1002/mds.870050202 · Cited by 218
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152

Flagged first, then by citations

Show all 19 references

Research works printed but not linked: 1

Reitan RM Wolfson D. The Halstead–Reitan Neuropsychological Test Battery. Tuscon: Neuropsychology Press 1958.

Sorted by citations

Items 101–200 of 311

The Adenosine A1Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity
Blum, D. L., Gall, D., Galas, M., d’Alcantara, P., Bantubungi, K., & Schiffmann, S. N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09122.2002 · Cited by 73
Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease
Reynolds, N. C., Prost, R. W., & Mark, L. P. (2004) · Brain Research · doi:10.1016/j.brainres.2004.10.030 · Cited by 73
Milestones in Huntington disease
Shoulson, I., & Young, A. B. (2011) · Movement Disorders · doi:10.1002/mds.23685 · Cited by 70
The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration
Leegwater‐Kim, J., & Cha, J.-H. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.128 · Cited by 68
Derivation of Huntington's Disease-Affected Human Embryonic Stem Cell Lines
Bradley, C. K., Scott, H. A., Chami, O., Peura, T., Dumevska, B., Schmidt, U., & Stojanov, T. (2011) · Stem Cells and Development · doi:10.1089/scd.2010.0120 · Cited by 72
Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review
Essa, M. M., Moghadas, M., Ba-Omar, T., Qoronfleh, M. W., Guillemin, G. J., Manivasagam, T., Justin‐Thenmozhi, A., Ray, B., Bhat, A., Chidambaram, S. B., et al. (2019) · Neurotoxicity Research · doi:10.1007/s12640-018-9989-9 · Cited by 68
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
Zádori, D., Klivènyi, P., Plangár, I., Toldi, J., & Vécsei, L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01237.x · Cited by 68
Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington’s Disease
del Hoyo, P., García‐Redondo, A., Bustos, F., Molina, J. A., Sayed, Y., Alonso‐Navarro, H., Caballero, L., Arenas, J., & Jiménez‐Jiménez, F. J. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9110-2 · Cited by 63
Simultaneous Confidence Intervals for Comparing Binomial Parameters
Agresti, A., Bini, M., Bertaccini, B., & Ryu, E. (2008) · Biometrics · doi:10.1111/j.1541-0420.2008.00990.x · Cited by 65
Clinical trials of coenzyme Q10 in neurological disorders
Shults, C. W., & Haas, R. (2005) · BioFactors · doi:10.1002/biof.5520250113 · Cited by 62
The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease
Gil‐Mohapel, J., & Rego, A. C. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.001 · Cited by 67
An overview of psychiatric symptoms in Huntington’s disease
Anderson, K. E., & Marder, K. S. (2001) · Current Psychiatry Reports · doi:10.1007/s11920-996-0030-2 · Cited by 63
Coenzyme Q10 effects in neurological diseases
Rauchová, H. (2021) · Physiological Research · doi:10.33549/physiolres.934712 · Cited by 68
Huntington's Disease: Pathological Mechanisms and Therapeutic Strategies
Ramaswamy, S., Shannon, K. M., & Kordower, J. H. (2007) · Cell Transplantation · doi:10.3727/000000007783464687 · Cited by 59
Ubisol-Q10 (a Nanomicellar Water-Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer’s Disease
Muthukumaran, K., Kanwar, A. S., Vegh, C., Marginean, A., Elliott, A., Guilbeault, N. C., Badour, A., Sikorska, M., Cohen, J. S., & Pandey, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170275 · Cited by 60
Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease
Beal, M. F., & Shults, C. W. (2003) · BioFactors · doi:10.1002/biof.5520180218 · Cited by 60
An evidence-based approach in the treatment of Huntington’s disease
Mestre, T., & Ferreira, J. J. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.10.021 · Cited by 57
Huntington’s disease: the coming of age
Pandey, M., & Rajamma, U. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0957-1 · Cited by 56
A review of the treatment options for Huntington?s disease
Bonelli, R. M., & Hofmann, P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.4.767 · Cited by 55
Neuroprotective Effects of Psychotropic Drugs in Huntington’s Disease
Lauterbach, E. C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122558 · Cited by 51
Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone
Liu, J., & Wang, L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0124-4 · Cited by 53
Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke
Tarawneh, R. M., & Galvin, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.12.003 · Cited by 54
Coenzyme Q10 (Ubiquinol-10) Supplementation Improves Oxidative Imbalance in Children With Trisomy 21
Miles, M. V., Patterson, B. J., Chalfonte-Evans, M., Horn, P. S., Hickey, F. J., Schapiro, M. B., Steele, P. E., Tang, P., & Hotze, S. L. (2007) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2007.08.003 · Cited by 52
Large-scale phenome analysis defines a behavioral signature for Huntington's disease genotype in mice
Alexandrov, V., Brunner, D., Menalled, L., Kudwa, A. E., Watson-Johnson, J., Mazzella, M. J., Russell, I., Ruiz, M. C., Torello, J., Sabath, E. V., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3587 · Cited by 51
Pharmaceutical, cellular and genetic therapies for Huntington's disease
Handley, O., Naji, J. J., Dunnett, S. B., & Rosser, A. (2005) · Clinical Science · doi:10.1042/cs20050148 · Cited by 51
Experimental therapeutics in Huntington's disease
Bates, G. P., & Hockly, E. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084223.82329.bb · Cited by 51
Pathogenic Mechanisms in Huntington's Disease
Jones, L., & Hughes, A. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00015-8 · Cited by 51
Kennedy's disease: pathogenesis and clinical approaches
Greenland, K. J., & Zajac, J. D. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00588.x · Cited by 48
An MDS Evidence‐Based Review on Treatments for Huntington's Disease
Ferreira, J. J., Rodrigues, F. B., Duarte, G. S., Mestre, T., Bachoud‐Lévi, A., Bentivoglio, A. R., Burgunder, J., Cardoso, F., Claassen, D. O., Landwehrmeyer, G. B., et al. (2021) · Movement Disorders · doi:10.1002/mds.28855 · Cited by 47
Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics
Ross, C. A., & Shoulson, I. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70800-4 · Cited by 47
Targeting Mitochondria for Neuroprotection in Parkinson's Disease
Schapira, A. H. V. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4419 · Cited by 46
Coenzyme Q10 and Neurological Diseases
Mancuso, M., Orsucci, D., Calsolaro, V., Choub, A., & Siciliano, G. (2009) · Pharmaceuticals · doi:10.3390/ph203134 · Cited by 46
Neuroprotection for Huntington’s Disease: Ready, Set, Slow
Hersch, S. M., & Rosas, H. D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.003 · Cited by 44
Mitochondrial matters of the brain: the role in Huntington’s disease
Turner, C., & Schapira, A. H. V. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9290-y · Cited by 45
Coenzyme Q10 levels are low and associated with increased mortality in post-cardiac arrest patients
Cocchi, M. N., Giberson, B., Berg, K. M., Salciccioli, J. D., Naini, A., Buettner, C., Akuthota, P., Gautam, S., & Donnino, M. W. (2012) · Resuscitation · doi:10.1016/j.resuscitation.2012.03.023 · Cited by 43
Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study
Aylward, E., Rosenblatt, A., Field, K., Yallapragada, V., Kieburtz, K. D., McDermott, M., Raymond, L. A., Almqvist, E. W., Hayden, M. R., & Ross, C. A. (2003) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2003.09.005 · Cited by 41
Targeting cellular energy production in neurological disorders
Baker, S. K., & Tarnopolsky, M. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.10.1655 · Cited by 43
Cell Rearrangement and Oxidant/Antioxidant Imbalance in Huntington’s Disease
D’Egidio, F., Castelli, V., Cimini, A., & d’Angelo, M. (2023) · Antioxidants · doi:10.3390/antiox12030571 · Cited by 42
Huntington's Disease: Advocacy Driving Science
Wexler, N. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050710-134457 · Cited by 40
An update on Huntington's disease
Kim, S. D., & Fung, V. S. C. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000116 · Cited by 42
The role of ferroptosis in neurodegenerative diseases
Xu, Y., Zhao, J., Zhao, Y., Zhou, L., Qiao, H., Xu, Q., & Liu, Y. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08048-y · Cited by 43
Prospects for neuroprotective therapies in prodromal Huntington's disease
Chandra, A., Johri, A., & Beal, M. F. (2014) · Movement Disorders · doi:10.1002/mds.25835 · Cited by 41
Metabolism in HD: Still a relevant mechanism?
Duan, W., Jiang, M., & Jin, J. (2014) · Movement Disorders · doi:10.1002/mds.25992 · Cited by 41
Sex-Dependent Changes in Social Behaviors in Motor Pre-Symptomatic R6/1 Mice
Pietropaolo, S., Delage, P., Cayzac, S., Crusio, W. E., & Cho, Y. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019965 · Cited by 43
Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model
Choo, Y. S., Mao, Z., Johnson, G. V. W., & Lesort, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.065 · Cited by 42
Effect on absorption and oxidative stress of different oral Coenzyme Q10dosages and intake strategy in healthy men
Singh, R. B., Niaz, M. A., Kumar, A., Sindberg, C., Moesgaard, S., & Littarru, G. P. (2005) · BioFactors · doi:10.1002/biof.5520250127 · Cited by 40
Neural Transplantation in Patients with Huntington???s Disease
Rosser, A., & Dunnett, S. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317120-00001 · Cited by 39
Recent Advances in the Treatment of Huntington’s Disease: Targeting DNA and RNA
Shannon, K. M. (2020) · CNS Drugs · doi:10.1007/s40263-019-00695-3 · Cited by 38
Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats
Morè, L., Gravius, A., Nagel, J., Valastro, B., Greco, S., & Danysz, W. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283123cad · Cited by 38
Huntington’s Disease Clinical Trials Corner: June 2019
Rodrigues, F. B., Ferreira, J. J., & Wild, E. J. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-199003 · Cited by 36
Symptomatic and Disease-Modifying Therapy for the Progressive Ataxias
Perlman, S. (2004) · The Neurologist · doi:10.1097/01.nrl.0000141651.35193.67 · Cited by 38
Dithiol-based Compounds Maintain Expression of Antioxidant Protein Peroxiredoxin 1 That Counteracts Toxicity of Mutant Huntingtin
Pitts, A., Dailey, K. M., Newington, J. T., Chien, A., Arseneault, R., Cann, T., Thompson, L. M., & Cumming, R. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334565 · Cited by 35
From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials
Heemskerk, J., Tobin, A. J., & Ravina, B. M. (2002) · Nature Neuroscience · doi:10.1038/nn931 · Cited by 36
Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease
Hickey, M. A., Zhu, C., Medvedeva, V. P., Franich, N. R., Levine, M. S., & Chesselet, M. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.10.007 · Cited by 35
New Directions in Therapeutics for Huntington Disease
Potkin, K. T., & Potkin, S. G. (2018) · Future Neurology · doi:10.2217/fnl-2017-0035 · Cited by 36
Revisiting the neuropsychiatry of Huntington's disease
Teixeira, A. L., de Souza, L. C., Rocha, N. P., Furr-Stimming, E. E., & Lauterbach, E. C. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1004002 · Cited by 34
Bioavailability and Sustained Plasma Concentrations of CoQ10 in Healthy Volunteers by a Novel Oral Timed-Release Preparation
Martucci, A., Reurean‐Pintilei, D., & Manole, A. (2019) · Nutrients · doi:10.3390/nu11030527 · Cited by 33
Neuroprotection in parkinson’s disease: An elusive goal
Koller, W. C., & Cersosimo, M. G. (2004) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-004-0052-2 · Cited by 33
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
McGarry, A. J., Leinonen, M., Kieburtz, K. D., Geva, M., Olanow, C. W., & Hayden, M. R. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200440 · Cited by 32
Novel therapeutic targets for Huntington’s disease
Hannan, A. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.639 · Cited by 32
Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
Sabbagh, M. N., & Shill, H. A. (2010) · PubMed · Cited by 32
Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease
Tobore, T. O. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24492 · Cited by 32
Biofluid Biomarkers in Huntington’s Disease
Rodrigues, F. B., Byrne, L. M., & Wild, E. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_17 · Cited by 30
Design and analysis of two-period studies of potentially disease-modifying treatments
McDermott, M., Hall, W. J., Oakes, D., & Eberly, S. W. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00238-6 · Cited by 29
Evidence from biomarkers and surrogate endpoints
Feigin, A. (2004) · NeuroRx · doi:10.1602/neurorx.1.3.323 · Cited by 29
Excitotoxicity in Huntington disease
Raymond, L. A. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00054-9 · Cited by 31
Rating Scales and Performance‐based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations
Mestre, T., Busse, M. E., Davis, A. M., Quinn, L., Rodrigues, F. B., Burgunder, J., Carlozzi, N. E., Walker, F. O., Ho, A. K., Sampaio, C., et al. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12617 · Cited by 29
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
Waters, N., Tedroff, J., Pontén, H., Klamer, D., Sonesson, C., & Waters, N. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170267 · Cited by 30
Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia
Maguire, Á., Hargreaves, A., & Gill, M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1556481 · Cited by 30
Emerging chemotherapeutic strategies for Huntington’s disease
Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30
Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials
Pagano, G., Talamanca, A. A., Castello, G., Cordero, M. D., d’Ischia, M., Gadaleta, M. N., Pallardó, F. V., Petrović, S. Ž., Tiano, L., & Zatterale, A. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151120169 · Cited by 26
A Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q10 (Ubiquinone)
Constantinescu, R., McDermott, M. P., DiCenzo, R., de Blieck, E. A., Hyson, H. C., Beal, M. F., Bednarczyk, E. M., Bogdanov, M. B., Metakis, L., Browne, S. E., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307571 · Cited by 27
Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders
Verma, A. K., Khan, E., Bhagwat, S. R., & Kumar, A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01724-4 · Cited by 28
Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes
Deschepper, M., Hoogendoorn, B., Brooks, S. P., Dunnett, S. B., & Jones, L. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.01.012 · Cited by 27
Combined Supplementation of Coenzyme Q10 and Other Nutrients in Specific Medical Conditions
Tippairote, T., Bjørklund, G., Gasmi, A., Semenova, Y. M., Peana, M., Chirumbolo, S., & Hangan, T. (2022) · Nutrients · doi:10.3390/nu14204383 · Cited by 28
Targeting aggregation in the development of therapeutics for the treatment of Huntington?s disease and other polyglutamine repeat diseases
Steffan, J. S., & Thompson, L. M. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.201 · Cited by 26
Huntington's disease: Objective assessment of posture—A link between motor and functional deficits
Reilmann, R., Rumpf, S., Beckmann, H., Koch, R., Ringelstein, E. B., & Lange, H. W. (2012) · Movement Disorders · doi:10.1002/mds.24908 · Cited by 25
Ubisol-Q10, a Nanomicellar and Water-Dispersible Formulation of Coenzyme-Q10 as a Potential Treatment for Alzheimer’s and Parkinson’s Disease
Wear, D., Vegh, C., Sandhu, J. K., Sikorska, M., Cohen, J., & Pandey, S. (2021) · Antioxidants · doi:10.3390/antiox10050764 · Cited by 16
Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases
Ebrahimi, A., Kamyab, A., Hosseini, S., Ebrahimi, S., & Ashkani‐Esfahani, S. (2023) · Biochemistry Research International · doi:10.1155/2023/5510874 · Cited by 29
Design and implementation of the first randomized controlled trial of coenzyme Q10 in children with primary mitochondrial diseases
Stacpoole, P. W., deGrauw, T. J., Feigenbaum, A. S. J., Hoppel, C. L., Kerr, D. S., McCandless, S. E., Miles, M. V., Robinson, B. H., & Tang, P. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.09.005 · Cited by 25
Coenzyme Q10 Absorption and Tolerance in Children With Down Syndrome: A Dose-Ranging Trial
Miles, M. V., Patterson, B. J., Schapiro, M. B., Hickey, F. J., Chalfonte-Evans, M., Horn, P. S., & Hotze, S. L. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.11.004 · Cited by 25
Why are there no proven therapies for genetic mitochondrial diseases?
Stacpoole, P. W. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.05.002 · Cited by 24
Therapeutics in Huntington’s Disease
Killoran, A., & Biglan, K. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0165-x · Cited by 23
Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration
Ardan, T., Baxa, M., Levinská, B., Sedláčková, M., Nguyen, T. D., Klı́ma, J., Juhás, Š., Juhásová, J., Šmatlíková, P., Vochozková, P., et al. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.041319 · Cited by 22
Effects of coenzyme Q10 on salivary secretion
Ryo, K., Ito, A., Takatori, R., Tai, Y., Arikawa, K., Seido, T., Yamada, T., Shinpo, K., Tamaki, Y., Fujii, K., et al. (2011) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2011.03.029 · Cited by 23
MR‐spectroscopic findings in juvenile‐onset Huntington's disease
Reynolds, N. C., Prost, R. W., Mark, L. P., & Joseph, S. A. (2008) · Movement Disorders · doi:10.1002/mds.22245 · Cited by 22
Milestones in movement disorders clinical trials: Advances and landmark studies
Olanow, C. W., Wunderle, K. B., & Kieburtz, K. D. (2011) · Movement Disorders · doi:10.1002/mds.23727 · Cited by 22
Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease
Boros, F. A., Klivènyi, P., Toldi, J., & Vécsei, L. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1549231 · Cited by 20
Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts
Esteves, S., Duarte‐Silva, S., & Maciel, P. (2016) · Medicinal Research Reviews · doi:10.1002/med.21425 · Cited by 22
Molecular biology of Huntington's disease
McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 21
Targeting energy metabolism in Huntington's disease
Walker, F. O., & Raymond, L. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16739-1 · Cited by 21
Huntington's Disease and Related Disorders
Anderson, K. E. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2004.10.001 · Cited by 22
A mitochondrial basis for Huntington’s disease: therapeutic prospects
Chakraborty, J., Rajamma, U., & Mohanakumar, K. P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1951-9 · Cited by 21
Experimental Models of HD and Reflection on Therapeutic Strategies
Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 20
Neuronutrition: An Emerging Concept
Topçuoğlu, M. A., & Arsava, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-53171-7_10 · Cited by 19
A transgenic minipig model of Huntington's disease shows early signs of behavioral and molecular pathologies
Askeland, G., Rodinová, M., Štufková, H., Dosoudilova, Z., Baxa, M., Šmatlíková, P., Bohuslavová, B., Klempíř, J., Nguyen, T. D., Kuśnierczyk, A., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035949 · Cited by 19
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease
McGarry, A. J., Kieburtz, K. D., Abler, V., Grachev, I. D., Gandhi, S. K., Auinger, P., Papapetropoulos, S., & Hayden, M. R. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170241 · Cited by 18
Pharmacological intervention in oxidative stress as a therapeutic target in neurological disorders
Sharma, S., Advani, D., Das, A., Malhotra, N., Khosla, A., Arora, V., Jha, A., Yadav, M., Ambasta, R. K., & Kumar, P. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab064 · Cited by 19
Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research
Akyol, S., Ashrafi, N., Yılmaz, A., Türkoğlu, O., & Graham, S. F. (2023) · Metabolites · doi:10.3390/metabo13121203 · Cited by 20
Cognitive assessment in Huntington disease clinical drug trials
Stout, J. C., Andrews, S. C., & Glikmann‐Johnston, Y. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00019-5 · Cited by 14

Authors: The Huntington Study Group
Corresponding author: The Huntington Study Group
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-08-14
Volume: 57
Issue: 3
Pages: 397-404
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.57.3.397
OpenAlex: W4245847463
Cited by: 312
References: 19
Citations by year: 2026: 2 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 3 · 2014: 9 · 2013: 5 · 2012: 16
FWCI: 7.24
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (NS R01-35284, R01NS035284)
National Center for Research Resources (RR-00044, RR 01066, RR 07122, M01RR001066, M01RR000044, RR00042, RR 00645, M01RR000042, M01RR000645)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords: Huntington's disease, coenzyme Q10, remacemide, functional decline, total functional capacity, disease-modifying therapy, early-stage Huntington's disease, adverse events, nausea and vomiting
MeSH terms: Acetamides, Adult, Coenzymes, Double-Blind Method, Female, Humans, Huntington Disease, Male, Middle Aged, Prognosis, Time Factors, Ubiquinone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks